
Biotech firm Bio-Techne's TECH.O shares rise 4.8% to $76 premarket
TECH beat Q2 earnings estimates, driven by growth in its protein sciences unit that develops biological compounds for research, diagnostics, and cell and gene therapy
The protein sciences unit's sales rose 7% to $211.6 mln
Company reports Q2 adj profit of 42 cents per share, above analysts' est of 39 cents - LSEG
Posts Q2 sales of $297 mln, above analysts' est of $285.7 mln - LSEG
TECH fell ~6% in 2024